Pheno Therapeutics granted two key patents protecting its selective GPR17 antagonist pipeline targeting neurological diseases

Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological and neurodegenerative diseases, today announced it has been granted two key patents protecting its selective GPR17 (G protein-coupled receptor 17) antagonist pipeline.

Fraser Murray, PhD, CEO, Pheno Therapeutics. Image Credit: Pheno Therapeutics

Patent GB2642355 covers a polymorph (crystalline form) of PTD802, the specific form of Pheno’s lead clinical candidate being taken into the clinic, extending protection beyond existing patents. This adds further protection alongside existing UCB patents exclusively licensed to Pheno, which provide composition-of-matter protection for PTD802 in many countries worldwide. Patent GB2700773covers a composition of matter IP for PTD939, the Company’s second program. Both PTD802 and PTD939 are GPR17 antagonists. The PTD939 composition of matter patent is the strongest form of protection for a new drug, securing the program as it enters IND-enabling studies, initially targeting amyotrophic lateral sclerosis.

PTD802 is a novel small molecule therapeutic designed to promote remyelination, with an initial focus on multiple sclerosis (MS), a neurological disease with high unmet medical need. The Company has already achieved clinical trial authorization (CTA) from the UK’s MHRA and Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for PTD802, giving clearance to proceed to the clinic in both the UK and the US. Developed under an exclusive worldwide license from UCB, PTD802 is the first GPR17 program to receive IND clearance, with the potential to deliver a new class of neuroprotective therapeutics. The first-in-human study, due to commence in Q4 2026, will evaluate safety and tolerability in healthy volunteers.

We are building a strong, layered IP position around GPR17 with two protected assets, one of which is already cleared for clinical study in the UK and US. The chemistry and development work carried out by the Pheno team has been instrumental in the success of these patent applications, which will now go on to support the long-term value of the pipeline. We look forward to providing further updates as we progress PTD802 to a first-in-human trial.”

Fraser Murray, PhD, CEO, Pheno Therapeutics

Both patents, issued from priority patent applications based on which subsequent PCT applications were filed (PTD802 “Polymorph” WO2026/008995 and PTD939 “Compounds” WO2025/243046), which are currently undergoing preparation for national or regional filings in several key territories worldwide.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Pheno Therapeutics. (2026, November 18). Pheno Therapeutics granted two key patents protecting its selective GPR17 antagonist pipeline targeting neurological diseases. News-Medical. Retrieved on November 18, 2026 from https://www.news-medical.net/news/20261118/Pheno-Therapeutics-granted-two-key-patents-protecting-its-selective-GPR17-antagonist-pipeline-targeting-neurological-diseases.aspx.

  • MLA

    Pheno Therapeutics. "Pheno Therapeutics granted two key patents protecting its selective GPR17 antagonist pipeline targeting neurological diseases". News-Medical. 18 November 2026. <https://www.news-medical.net/news/20261118/Pheno-Therapeutics-granted-two-key-patents-protecting-its-selective-GPR17-antagonist-pipeline-targeting-neurological-diseases.aspx>.

  • Chicago

    Pheno Therapeutics. "Pheno Therapeutics granted two key patents protecting its selective GPR17 antagonist pipeline targeting neurological diseases". News-Medical. https://www.news-medical.net/news/20261118/Pheno-Therapeutics-granted-two-key-patents-protecting-its-selective-GPR17-antagonist-pipeline-targeting-neurological-diseases.aspx. (accessed November 18, 2026).

  • Harvard

    Pheno Therapeutics. 2026. Pheno Therapeutics granted two key patents protecting its selective GPR17 antagonist pipeline targeting neurological diseases. News-Medical, viewed 18 November 2026, https://www.news-medical.net/news/20261118/Pheno-Therapeutics-granted-two-key-patents-protecting-its-selective-GPR17-antagonist-pipeline-targeting-neurological-diseases.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Comments are closed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.